SCHEMBL24801038

SCHEMBL24801038

O=C1CC[C@H](c2c(F)cccc2F)C(=O)N1

nearest known ligand 0.57

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 20/20 0.57
DDB1 Q16531 19/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29348737 0.81 CRBN (0.47) CRBNDDB1
SCHEMBL24206784 0.80 CRBN (0.49) CRBNDDB1
SCHEMBL24204353 0.80 CRBN (0.46) CRBNDDB1
SCHEMBL25239091 0.80 CRBN (0.46) CRBNDDB1
SCHEMBL24207878 0.80 CRBN (0.55) CRBNDDB1
SCHEMBL30087084 0.80 CRBN (0.46) CRBNDDB1
SCHEMBL31192256 0.80 CRBN (0.46) CRBNDDB1
SCHEMBL31068344 0.77 CRBN (0.44) CRBNDDB1
SCHEMBL29348716 0.77 CRBN (0.44) CRBNDDB1
SCHEMBL24204588 0.76 CRBN (0.46) CRBNDDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240207267-A1 (R)-Glutarimide CRBN Ligands and Methods of Use BEIGENE SWITZERLAND GMBH (CH) 2024-06-27 US disclosed
WO-2022268052-A9 (R) -GLUTARIMIDE CRBN LIGANDS AND METHODS OF USE BEIGENE, LTD. (KY) 2023-08-17 WO disclosed
WO-2022268052-A1 (R) -GLUTARIMIDE CRBN LIGANDS AND METHODS OF USE BEIGENE, LTD. (KY) 2022-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240207267-A1 (R)-Glutarimide CRBN Ligands and Methods of Use CRBN, CDR2, CRKL CRBN 1/4885DDB1 220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.